ATM and ovarian cancer: In ovarian cancer, case-control studies mainly enriched for a family history of breast or ovarian cancer, have suggested that pathogenic or likely pathogenic variants in ATM might be associated with moderate increased risk (OR 1.69, 95% CI 1.2–2.4 [26]; Standardized risk ratio (SRR) 2.25, 95% CI 1.7–3 [27]; OR 1.97, 95% CI 1.3–3 [29]; OR 2.4, 95% CI 1.2–4.7 [35]; OR 2.85, 95% CI 1.3–6.3 [57]), however the cumulative lifetime risk has been estimated to be lower than 3%.